Every 424B that Protara Therapeutics, Inc. (TARA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TARA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TARA filings page.
Protara Therapeutics (TARA) has filed a prospectus supplement to sell up to $100,000,000 of common stock through an at-the-market sales agreement with TD Securities (USA) LLC (TD Cowen). Shares may be sold from time to time under the Sales Agreement, which permits sales on Nasdaq or by other methods permitted by law.
This offering is part of a $300,000,000 shelf registration. The prospectus supplement states last reported sale price of $5.27 per share on May 11, 2026 and uses proceeds to fund clinical development of TARA-002, IV Choline Chloride and other programs. The Sales Agreement allows TD Cowen to act as agent or principal, with compensation up to 3.0% of gross proceeds, and contains customary indemnification provisions.
Protara Therapeutics is registering up to 21,686,760 shares of common stock for resale by selling stockholders. This prospectus supplement updates the May 9, 2024 prospectus and breaks the 21,686,760 shares into 9,143,380 Initial Shares, 1,700,000 Pre-Funded Warrant Shares and 10,843,380 Common Warrant Shares.
The supplement adds selling holders and updates the selling stockholder table as of March 6, 2026, including assignments of Common Warrants for up to 200,000 warrant shares to Warberg Special Situations Fund LP and 200,000 warrant shares to Warberg WF XIII LP. Beneficial ownership limits for those holders are listed at 4.99%.
Protara Therapeutics, Inc. filed a prospectus supplement updating its existing resale registration covering up to 21,686,760 shares of common stock. These shares include currently held common stock as well as shares issuable upon exercise of pre-funded warrants and common warrants held by selling stockholders.
The update adds Funicular Funds, LP as a selling stockholder following an assignment on January 28, 2026 by OTA Trading Fund 1 LLC of common warrants exercisable for up to 142,400 common stock warrant shares. Funicular Funds, LP does not own common stock as of January 30, 2026 and is subject to a 4.99% beneficial ownership limitation after warrant exercises.